AMRX vs ZBH · P/E 44, rev $1.52B vs P/E 23, rev $4.26B
Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) versus Zimmer Biomet Holdings Inc (ZBH) — a side-by-side from cached financials, not a winner call.
Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) is a drug manufacturers - specialty & generic company listed on NASDAQ.
Zimmer Biomet Holdings Inc (ZBH) is a medical devices company listed on NYSE.
Latest reported AMRX revenue for 2026-06-30 was $1.52B. Net income was $119.9M. AMRX currently screens at market cap $5.19B and trailing P/E 44.0.
Latest reported ZBH revenue for 2026-06-30 was $4.26B. Net income was $436.5M. ZBH currently screens at market cap $17.13B and trailing P/E 22.9.
AMRX currently screens at market cap $5.19B and trailing P/E 44.0. ZBH currently screens at market cap $17.13B and trailing P/E 22.9.
Not investment advice. Open the AMRX and ZBH stock pages for the full models.
Not investment advice.